DaVita Inc.
DVA Healthcare Medical Care Facilities
DaVita Inc.’s revenue for fiscal 2025 (year ended December 2025) was $13.6 billion, up 6.46% from fiscal 2024.
- Revenue
- +4.62%
- EPS
- +67.0%
- Free cash flow
- −45.8%
- Total debt
- +5.07%
Quarter to September 2026, against a year earlier
Follow DVA
Alert me
DaVita Inc. (DVA) valuation and DCF model
At $189.65 the price implies free cash flow after share-based pay growing 5.4% a year for ten years.
Free cash flow after share-based pay grew 3.2% a year over the last ten years, 1.1% over the last five. The price asks for about twice its ten-year rate. The industry’s median company is priced for 8.0%.
In December 2017 the price assumed 4.8% a year; DaVita Inc. went on to grow free cash flow after share-based pay 1.6% a year to FY2025.
- The price needs
- 5.4% a year for ten years
- $189.65
- today’s price
- Its base case
- 3.2% a year for five years, then 1.9%
- $126.77
- 33.2% below today’s price
Base case on its own ten-year record DaVita Inc.’s own growth, carried forward
Its assumptions
Powerpack lets you start from a scenario and type over any of them.
How we got there$8.76b 10 years of cash to equity+$10.17b terminal value−$10.17b net debt=$8.76b equity value÷69.09m shares=$126.77 per share
Valuation against its own history
| Multiple | Current | 5Y avg | 10Y avg | vs 10Y avg | Industry median | vs industry | 10Y range |
|---|---|---|---|---|---|---|---|
| P/E | 14.01× | 13.07× | 19.17× | 27% below | 17.41× | 20% below | |
| P/FCF | 8.36× | 6.65× | 7.66× | 9% above | 16.05× | 48% below | |
| P/B | — | 13.92× | 9.15× | — | 3.12× | — | |
| EV/EBITDA | 8.01× | 7.42× | 8.01× | 0% below | 11.86× | 32% below | |
| EV/Sales | 1.59× | 1.47× | 1.63× | 2% below | 1.37× | 16% above |
DVA trades at 8.36× P/FCF, against a 10-year average of 7.66× (range 2.22×–12.45×). That is dearer than 56% of the last 9 year-end readings; re-rating to the average implies $173.84 per share.